Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.

ABSTRACT: The HIV infection is responsible for the most devastating global pandemic of the last century. More than 39 million people have died of HIV/AIDS since 1981. The development of the antiretroviral (ARV) treatment begins with the discovery of zidovudine a nucleoside reverse transcriptase inhibitor. This breakthrough was followed by other ARV drug classes and representatives. Presently, HIV treatment employs 27 ARV representatives belonging to five different classes. Despite the proven benefits of ARV treatment and its long-term control of the HIV infection, there is an increasing concern about the numerous adverse effects and resistance to current ARV drugs. Therefore, the new HIV treatment strategies focus on the development of new ARV agents with a high genetic barrier to resistance and low

SUBMITTER: Iacob SA 

PROVIDER: S-EPMC5711820 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature